TaiRx, Inc.
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various … Read more
TaiRx, Inc. (6580) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.139x
Based on the latest financial reports, TaiRx, Inc. (6580) has a cash flow conversion efficiency ratio of -0.139x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-80.17 Million) by net assets (NT$577.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TaiRx, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how TaiRx, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
TaiRx, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TaiRx, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mostostal Zabrze - Holding SA
WAR:MSZ
|
0.106x |
|
Data Image Corporation
TW:3168
|
0.054x |
|
ITM Semiconductor Co. Ltd
KQ:084850
|
0.015x |
|
Eimco Elecon (India) Limited
NSE:EIMCOELECO
|
0.013x |
|
Tze Shin International Co Ltd
TW:2611
|
-0.027x |
|
209640
KQ:209640
|
0.028x |
|
Nanoform Finland Plc
HE:NANOFH
|
-0.076x |
|
ONEJOON Co. Ltd.
KQ:382840
|
0.080x |
Annual Cash Flow Conversion Efficiency for TaiRx, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of TaiRx, Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$648.51 Million | NT$-149.81 Million | -0.231x | +8.36% |
| 2023-12-31 | NT$773.12 Million | NT$-194.88 Million | -0.252x | +34.95% |
| 2022-12-31 | NT$479.12 Million | NT$-185.66 Million | -0.388x | -110.53% |
| 2021-12-31 | NT$675.86 Million | NT$-124.41 Million | -0.184x | -3.46% |
| 2020-12-31 | NT$797.95 Million | NT$-141.97 Million | -0.178x | +51.79% |
| 2019-12-31 | NT$457.57 Million | NT$-168.87 Million | -0.369x | -- |